Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer
Aim: To evaluate the efficacy and safety of neratinib as extended adjuvant therapy in patients from Asia based on exploratory analyses of the Phase III ExteNET trial. Patients & methods: A total of 2840 women with early stage HER2-positive breast cancer were randomly assigned to neratinib 240 mg...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
Future Medicine
2019
|
| Subjects: | |
| Online Access: | http://eprints.um.edu.my/24103/ https://doi.org/10.2217/fon-2019-0143 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| id |
my.um.eprints.24103 |
|---|---|
| record_format |
eprints |
| spelling |
my.um.eprints.241032020-03-26T04:50:17Z http://eprints.um.edu.my/24103/ Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer Iwata, Hiroji Masuda, Norikazu Kim, Sung-Bae Inoue, Kenichi Rai, Yoshiaki Fujita, Takashi Chiu, Joanne Ohtani, Shoichiro Takahashi, Masato Miyaki, Toshiko Lu, Yen-Shen Xu, Binghe Yap, Yoon Sim Bustam, Anita Zarina Yao, Bin Zhang, Bo Bryce, Richard Chan, Arlene R Medicine Aim: To evaluate the efficacy and safety of neratinib as extended adjuvant therapy in patients from Asia based on exploratory analyses of the Phase III ExteNET trial. Patients & methods: A total of 2840 women with early stage HER2-positive breast cancer were randomly assigned to neratinib 240 mg/day or placebo for 1 year after trastuzumab-based adjuvant therapy. Results: A total of 341 patients were from Asia (neratinib, n = 165; placebo, n = 176). 2-year invasive disease-free survival rates were 92.8 and 90.8% with neratinib and placebo, respectively (HR: 0.70; 95% CI: 0.31-1.55), and 5-year rates were 91.9 and 87.2%, respectively (HR: 0.57; 95% CI: 0.27-1.13). Diarrhea was the most common adverse event with neratinib. Conclusion: Extended adjuvant therapy with neratinib reduces disease recurrences in Asian women with HER2-positive breast cancer. Trial registration: Clinicaltrials.gov NCT00878709. © 2019 Future Medicine Ltd. Future Medicine 2019 Article PeerReviewed Iwata, Hiroji and Masuda, Norikazu and Kim, Sung-Bae and Inoue, Kenichi and Rai, Yoshiaki and Fujita, Takashi and Chiu, Joanne and Ohtani, Shoichiro and Takahashi, Masato and Miyaki, Toshiko and Lu, Yen-Shen and Xu, Binghe and Yap, Yoon Sim and Bustam, Anita Zarina and Yao, Bin and Zhang, Bo and Bryce, Richard and Chan, Arlene (2019) Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer. Future Oncology, 15 (21). pp. 2489-2501. ISSN 1479-6694 https://doi.org/10.2217/fon-2019-0143 doi:10.2217/fon-2019-0143 |
| institution |
Universiti Malaya |
| building |
UM Library |
| collection |
Institutional Repository |
| continent |
Asia |
| country |
Malaysia |
| content_provider |
Universiti Malaya |
| content_source |
UM Research Repository |
| url_provider |
http://eprints.um.edu.my/ |
| topic |
R Medicine |
| spellingShingle |
R Medicine Iwata, Hiroji Masuda, Norikazu Kim, Sung-Bae Inoue, Kenichi Rai, Yoshiaki Fujita, Takashi Chiu, Joanne Ohtani, Shoichiro Takahashi, Masato Miyaki, Toshiko Lu, Yen-Shen Xu, Binghe Yap, Yoon Sim Bustam, Anita Zarina Yao, Bin Zhang, Bo Bryce, Richard Chan, Arlene Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer |
| description |
Aim: To evaluate the efficacy and safety of neratinib as extended adjuvant therapy in patients from Asia based on exploratory analyses of the Phase III ExteNET trial. Patients & methods: A total of 2840 women with early stage HER2-positive breast cancer were randomly assigned to neratinib 240 mg/day or placebo for 1 year after trastuzumab-based adjuvant therapy. Results: A total of 341 patients were from Asia (neratinib, n = 165; placebo, n = 176). 2-year invasive disease-free survival rates were 92.8 and 90.8% with neratinib and placebo, respectively (HR: 0.70; 95% CI: 0.31-1.55), and 5-year rates were 91.9 and 87.2%, respectively (HR: 0.57; 95% CI: 0.27-1.13). Diarrhea was the most common adverse event with neratinib. Conclusion: Extended adjuvant therapy with neratinib reduces disease recurrences in Asian women with HER2-positive breast cancer. Trial registration: Clinicaltrials.gov NCT00878709. © 2019 Future Medicine Ltd. |
| format |
Article |
| author |
Iwata, Hiroji Masuda, Norikazu Kim, Sung-Bae Inoue, Kenichi Rai, Yoshiaki Fujita, Takashi Chiu, Joanne Ohtani, Shoichiro Takahashi, Masato Miyaki, Toshiko Lu, Yen-Shen Xu, Binghe Yap, Yoon Sim Bustam, Anita Zarina Yao, Bin Zhang, Bo Bryce, Richard Chan, Arlene |
| author_facet |
Iwata, Hiroji Masuda, Norikazu Kim, Sung-Bae Inoue, Kenichi Rai, Yoshiaki Fujita, Takashi Chiu, Joanne Ohtani, Shoichiro Takahashi, Masato Miyaki, Toshiko Lu, Yen-Shen Xu, Binghe Yap, Yoon Sim Bustam, Anita Zarina Yao, Bin Zhang, Bo Bryce, Richard Chan, Arlene |
| author_sort |
Iwata, Hiroji |
| title |
Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer |
| title_short |
Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer |
| title_full |
Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer |
| title_fullStr |
Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer |
| title_full_unstemmed |
Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer |
| title_sort |
neratinib after trastuzumab-based adjuvant therapy in patients from asia with early stage her2-positive breast cancer |
| publisher |
Future Medicine |
| publishDate |
2019 |
| url |
http://eprints.um.edu.my/24103/ https://doi.org/10.2217/fon-2019-0143 |
| _version_ |
1662755223446224896 |
| score |
13.211869 |